

Docket No.: 1422-0709PUS1

(PATENT)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mitsuko IDENO et al.

Application No.: 10/568,745

LYMPHOCYTES

Confirmation No.: 6655

Filed: February 21, 2006

Art Unit: 1636

For: PROCESS FOR PRODUCING CYTOTOXIC

Examiner: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

#### I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

#### II. **COPIES**

冈 a. Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.

Application No.: 10/568,745

Docket No.: 1422-0709PUS1

	a.	This Information Disclosure Statement is being filed concurrently with the filing
of a ne	ew pater	nt application; therefore, no fee is required.
	b.	This Information Disclosure Statement is being filed concurrent with the filing of
		-in-part, continuation, or divisional patent application; therefore, no fee is required.
	c.	This Information Disclosure Statement is being filed within three months of the
filing	date of	a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required.
(This s	section i	s not to be used with RCE's.)
	d.	This Information Disclosure Statement is being filed within three months of the
— date o	f entry c	of the national stage as set forth in § 1.491 in an international application (37 C.F.R.
§ 1.97	(b)(2)).	No fee or statement is required.
	e.	This Information Disclosure Statement is being filed concurrently with the filing
		for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or
statem	ent is re	equired.
$\boxtimes$	f.	This Information Disclosure Statement is being filed before the mailing date of a
first A	ction or	the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event
that a	first Off	fice Action on the merits has been issued, please consider this IDS under 37 C.F.R.
§ 1.97	(c) and	see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been
made,	charge	our deposit account for the fee as required by 37 C.F.R. § 1.17(p).
	g.	This Information Disclosure Statement is being filed before the mailing date of a
— Final (	_	Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing
		ce of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).
		No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.
	or	
	☐ See	the statement below. No fee is required.
		3 MSW/TJS/wmm

Docket No.: 1422-0709PUS1

Application No.: 10/568,745

Application No.: 10/568,745 Docket No.: 1422-0709PUS1

# V. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) The undersigned hereby states that: П a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or Each item of information contained in the IDS was first cited in any b. communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or No item of information contained in the IDS was cited in a communication from a c. foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. VI. <u>PAYMENT OF FEES</u> (check one box)

The required fee is listed on the attached Fee Transmittal.

Application No.: 10/568,745 Docket No.: 1422-0709PUS1

 $\boxtimes$  No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated:

August 23, 2007

Respectfully submitted,

Marc S. Weiner

Registration No.: 32,181

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

Attachment(s):

PTO/SB/08

Document(s)

Foreign Office Action

Fee

Other:

Used in Lieu of PTO/SB/08A/B (Based on PTO 04-07 version)

AUG 2 3 2001 B

1 ,	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/568,745	
	INFORMATIO	N DI	SCLOSURE	Filing Date	February 21, 2006	
	STATEMENT BY APPLICANT			First Named Inventor	Mitsuko IDENO	
				Art Unit	1636	
	(Use as many sh	eets as	necess ary)	Examiner Name	Not Yet Assigned	
She	et 1	of	1	Attorney Docket Number	1422-0709PUS1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	Π	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Description	Where Relevant Passages Or Relevant Figures Appear		
	BA	WO-96/00782-A1	01-11-1996			Г	
	ВВ	WO-95/11963-A1	05-04-1995			Γ	
	ВС	WO-95/04078-A1	02-09-1995			Γ	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nationally in the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	"Animal Cell Culture," Freshney, Ed., 1986, IRL Press, Oxford, Washington DC, Sections 2.1,3.2.2-3.2.6,5,6.1-6.3,3.1-3.4	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Date Signature Considered			
Todiatae I	Examiner	Date	
	I Didilatare I	Considered	



<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.